Over the next three years, large and small health plans and PBMs that are currently involved in emerging health information technologies are going to focus on increasing disease management programs and on providing personal digital assistants (such as the Palm) to physicians, according to a report by the Foundation for Managed Care Pharmacy, the educational arm of the Academy of Managed Care Pharmacy.

"The benefits these technologies will deliver will be an enhancement of quality care for the patient and an increased efficiency in the system. Emerging technologies will take some of the administrative costs out of the system — once the technology is up and running," says Cynthia J. Pigg, executive director of the foundation. In particular, DM programs' use of predictive modeling will increase.

These patient-oriented technologies seem to be on the horizon because early electronic efforts were focused on paying the provider, says Pigg. She adds that "Pharmacy claims have used electronic billing systems since the 1990s, and improvements to create greater efficiency have been made along the way." Once the challenges associated with billing are overcome and the "system made more efficient, then the focus shifts to patient care," says Pigg.

The report, "Benchmarking New Frontiers in Managed Care Pharmacy — Emerging Trends Research with Managed Pharmacy Experts," found that only about half the respondents had begun the process of designing or implementing electronic prescribing technologies, but for those that had begun, more than 20 percent were within a year of implementing a program. About one third of the largest organizations had an operational system in place, and another 13 percent were nearly there.

Which will be operational within three years?

Note: Respondents could select all that apply

Source: Foundation for Managed Care Pharmacy

CHARTS BY JULIE RIDGE

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.